Vanda Pharmaceuticals’ (VNDA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report released on Tuesday,Benzinga reports. HC Wainwright currently has a $18.00 price objective on the biopharmaceutical company’s stock.

Separately, StockNews.com assumed coverage on Vanda Pharmaceuticals in a research note on Tuesday, January 28th. They issued a “hold” rating on the stock.

Vanda Pharmaceuticals Stock Up 3.5 %

NASDAQ:VNDA opened at $4.69 on Tuesday. The stock’s 50-day simple moving average is $4.66 and its 200 day simple moving average is $4.92. The firm has a market capitalization of $273.47 million, a PE ratio of -16.75 and a beta of 0.74. Vanda Pharmaceuticals has a twelve month low of $3.61 and a twelve month high of $6.75.

Insider Buying and Selling at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $5.17, for a total value of $25,850.00. Following the completion of the transaction, the director now directly owns 44,857 shares in the company, valued at approximately $231,910.69. This trade represents a 10.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 8.90% of the company’s stock.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Large investors have recently bought and sold shares of the company. ORG Wealth Partners LLC bought a new position in Vanda Pharmaceuticals in the third quarter valued at about $40,000. China Universal Asset Management Co. Ltd. raised its position in shares of Vanda Pharmaceuticals by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 4,374 shares during the last quarter. Intech Investment Management LLC bought a new position in shares of Vanda Pharmaceuticals during the third quarter worth about $84,000. SG Americas Securities LLC raised its position in shares of Vanda Pharmaceuticals by 88.5% during the third quarter. SG Americas Securities LLC now owns 20,402 shares of the biopharmaceutical company’s stock worth $96,000 after acquiring an additional 9,580 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of Vanda Pharmaceuticals during the third quarter worth about $143,000. 88.14% of the stock is currently owned by institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.